Rein Therapeutics Inc.
RNTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $14,248 | $4 | $18 | $17 |
| G&A Expenses | $13,864 | $11 | $10 | $10 |
| SG&A Expenses | $13,864 | $11 | $10 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $37,000 | $1 | $0 | $0 |
| Operating Expenses | $65,112 | $16 | $28 | $27 |
| Operating Income | -$65,112 | -$16 | -$28 | -$27 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $800 | $1 | $0 | $0 |
| Pre-Tax Income | -$64,312 | -$16 | -$27 | -$26 |
| Tax Expense | -$1,544 | $0 | $0 | $0 |
| Net Income | -$62,883 | -$16 | -$27 | -$26 |
| % Margin | – | – | – | – |
| EPS | -3.51 | -3.42 | -6.02 | -5.89 |
| % Growth | -2.6% | 43.2% | -2.2% | – |
| EPS Diluted | -3.51 | -3.42 | -6.02 | -5.89 |
| Weighted Avg Shares Out | 18 | 5 | 5 | 4 |
| Weighted Avg Shares Out Dil | 18 | 5 | 5 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $400 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $63 | $0 | $0 | $0 |
| EBITDA | -$28,049 | -$15 | -$27 | -$26 |
| % Margin | – | – | – | – |